Novartis advances IgAN efforts with phase 3 win for Fabhalta, plots FDA filing for full approval
16th October 2025 Uncategorised 0At the final analysis of the phase 3 Applause-IgAN trial, Novartis’ complement factor B inhibitor Fabhalta showed that it can slow kidney function decline and IgAN progression, the company said. Novartis plans to leverage the data for regulatory submissions next year.
More: Novartis advances IgAN efforts with phase 3 win for Fabhalta, plots FDA filing for full approval
Source: fierce